Efficacy of Human Gut microbiota-derived consortium complex for irritable bowel syndrome patients
Not Applicable
Completed
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0007709
- Lead Sponsor
- Hallym University Medical Center-Kangnam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
patients (19 years or older) who met the Rome IV criteria for the diagnosis of IBS were eligible to participate.
Exclusion Criteria
The exclusion criteria were previous abdominal surgery except appendectomy and Caesarian section, inflammatory bowel syndrome, and concurrent severe illness (cancer, cardiovascular or pulmonary disease). In addition, patients who had used antipsychotics, antibiotics, and probiotics within the two weeks were also excluded.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of IBS Symptom Severity assessed with the IBS Severity Scoring System (50 points or more decrease) : Assessed using IBS SSS Questionnaire
- Secondary Outcome Measures
Name Time Method Change of abdominal pain Severity assessed with the IBS Severity scoring System (10 points or more decrease) : Assessed using IBS SSS Questionnaire;Change of Irritable Bowel Syndrome Quality of Life Score (10 points or more decrease) : Assessed using IBS- QOL Questionnaire